SAB Biotherapeutics Gets Another $8.2 million from Department of Defense in Closeout Settlement
By Exec Edge Editorial Staff Immunotherapy-focused SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and...